




ELSEVIER

Contents lists available at ScienceDirect

Digestive and Liver Disease

journal homepage: www.elsevier.com/locate/dld

Liver, Pancreas and Biliary Tract

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort



Maria Giovanna Quaranta^a, Luigina Ferrigno^a, Xhimi Tata^b, Franca D'Angelo^a, Marco Massari^c, Carmine Coppola^d, Elisa Biliotti^e, Alessia Giorgini^f, Diletta Laccabue^g, Alessia Ciancio^h, Pier Luigi Blancⁱ, Marzia Margotti^j, Donatella Ieluzzi^k, Maurizia Rossana Brunetto^l, Francesco Barbaro^m, Francesco Paolo Russoⁿ, Iliaria Beretta^o, Giulia Morsica^p, Gabriella Verucchi^q, Annalisa Saracino^r, Massimo Galli^s, Loeta A. Kondili^{a,*}, on behalf of PITER Collaborating Group[#]

^a Center for Global Health, Istituto Superiore di Sanità, Rome, Italy^b University of Tor Vergata, Nostra Signora del Buon Consiglio di Tirana, Albania^c Infectious Diseases, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Italy^d Department of Hepatology, Gragnano Hospital, Naples, Italy^e Hepatology Unit, Department of Clinical Medicine, Sapienza University, Rome, Italy^f Gastroenterology and Hepatology Unit, ASST Santi Paolo e Carlo, Milan, Italy^g Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy^h Gastroenterology Unit, University of Turin, Turin, Italyⁱ Infectious Disease Unit, Santa Maria Annunziata Hospital, Florence, Italy^j Department of Internal Medicine, University Hospital of Modena, Italy^k Clinical Unit of Gastroenterology, University Hospital of Verona, Verona, Italy^l Hepatology and Liver Physiopathology Laboratory and Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy^m Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padua, Italyⁿ Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy^o Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy^p Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy^q Department of Medical and Surgical Sciences, Clinic of Infectious Diseases and Microbiology Unit, Alma Mater Studiorum Bologna University, Bologna, Italy^r Division of Infectious Diseases, Bari University Hospital, University of Bari, Italy^s Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Italy

ARTICLE INFO

Article history:

Received 4 December 2020

Revised 8 March 2021

Accepted 15 March 2021

Available online 21 April 2021

Key words:

HCV Cohort

Linked-to-care patients

Comorbidities

Direct acting antivirals

ABSTRACT

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort.

Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used.

Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, ($p < 0.001$), females 56.5% vs. 45.3%, ($p < 0.001$), HBsAg positivity 3.8% vs. 1.4%, ($p < 0.05$). Genotype 1b was prevalent in both groups, whereas genotype 4 was more prevalent in migrants ($p < 0.05$). Liver disease severity and sustained virologic response (SVR) were similar. A higher prevalence of comorbidities was reported for natives compared to migrants ($p < 0.05$). Liver disease progression cofactors (HBsAg, HIV coinfection, alcohol abuse, potential metabolic syndrome) were present in 39.1% and 47.1% ($p > 0.05$) of migrants and natives who eradicated HCV, respectively.

* Corresponding author.

E-mail address: loreta.kondili@iss.it (L.A. Kondili).

PITER Collaborating group: names and affiliations of each member of this study group are listed in Appendix.

<https://doi.org/10.1016/j.dld.2021.03.020>1590-8658/© 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Conclusion: Compared to natives, HCV-infected migrants in care have different demographics, HCV genotypes, viral coinfections and comorbidities and similar disease severity, SVR and cofactors for disease progression after HCV eradication. A periodic clinical assessment after HCV eradication in Italians and migrants with cofactors for disease progression is warranted.

© 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
This is an open access article under the CC BY-NC-ND license
(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Introduction

Chronic infection with hepatitis C virus (HCV) is a global public health challenge and a leading cause of liver disease-related morbidity and mortality. It has been estimated that over 71 million people have chronic hepatitis C infection, mainly among populations of Eastern Mediterranean and European Regions [1–4]. Persistent HCV infection is associated with the development of hepatic cirrhosis, hepatocellular carcinoma, liver failure and death [5,6].

Based on European Center for Disease Prevention and Control (ECDC) data [7], 14% of all chronic HCV hepatitis in Europe, and about 5% in Italy, affect migrants. It has been reported that Italy is the country with the highest prevalence rate of HCV in general population in Europe [8], whereas representative data on HCV prevalence rate in migrants are not available.

The availability of the second-generation direct acting antivirals (DAAs) has led to a high rate of HCV eradication. DAAs achieve cure rates over 98% in both clinical trials and real-world practice [9–11] regardless of race/ethnicity and HCV genotypes [12,13]. In patients without cirrhosis who achieve an SVR, the HCV infection can be considered as definitively cured. However, EASL Clinical Practice Guidelines suggest that patients with pre-existing cofactors for liver disease (notably, history of excessive alcohol drinking, obesity and/or type 2 diabetes) should be carefully and periodically subjected to a thorough clinical assessment, as needed [12]. The presence of cofactors for liver disease progression is common in patients with HCV who receive antiviral therapy in Italy, and might be different in the migrant population in care. Only few studies have examined the clinical profile of the linked to care foreign-born HCV infected patients. Thus, the aim of this study was to evaluate demographic, virological and clinical data of HCV-infected migrants in care in Italy as compared to native Italians. In particular, we aimed to underline the pattern of comorbidities and other factors for liver disease progression that should be focused in the clinical practice after HCV eradication.

Methods

Patients

Patients' data from the Italian Platform for the study of viral hepatitis therapy (PITER) cohort [14] between April 2014 and June 2019 were evaluated.

For each consecutively enrolled patient, baseline demographic, clinical and laboratory characteristics were recorded prior to the start of treatment. Migrants were defined as persons with country of birth and nationality different from Italy, whereas natives include persons born in Italy and with Italian nationality.

Fibrosis stage was defined based on liver transient elastography data, which were considered as validated if each patient had at least 10 available stiffness measurements, with a success rate of at least 80%, an interquartile range of less than 30% of the median stiffness score, and a body mass index (BMI) of $<30 \text{ kg/m}^2$ [15]. Liver cirrhosis was defined when the stiffness score was equal to or higher than 14 kPa or according to biochemical and instrumental

data of portal hypertension [15]. Decompensated cirrhosis was diagnosed according to the presence or appearance of ascites and/or gastrointestinal bleeding due to portal hypertension and/or hepatic encephalopathy and/or icterus and/or and spontaneous bacterial peritonitis.

Regarding the presence of cofactors for liver disease progression, the available data collected in the electronic case report form during the enrollment and following HCV eradication were evaluated. Specifically: potential metabolic syndrome (i.e. the presence of ultrasound fat and hypertension/cardiovascular disease or type 2 diabetes or $\text{BMI} > 25 \text{ kg/m}^2$ in patients who did not report), HBsAg positivity, HIV coinfection or current alcohol abuse (defined as 63 drinking more than 3 alcohol units/day [16]) were considered as cofactors for liver disease progression after HCV eradication.

Statistical analysis

Age at baseline was reported as median and ranges and all other categorical variables as proportions (N and %). The Mann-Whitney U test was used to assess differences between age distribution and the Chi-squared test was used for comparison among proportions. A p-value <0.05 was considered statistically significant.

Adjusted Odds Ratios for potential confounding variables (i.e. age, sex, BMI, HCV genotype, HBsAg positivity, HIV coinfection, alcohol use, previous interferon-based treatment, liver stiffness value) were calculated by multiple logistic regression using migrant status as the dependent variable.

All analyses were performed using the STATA/SE 16.1 statistical package (StataCorp LP, College Station, TX, USA).

Ethics

The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. The study protocol was approved by the Ethics Committee of the Istituto Superiore di Sanità (Italian National Institute of Public Health) and by the local Ethics committees of each clinical center. Patients' data were evaluated through an anonymous analysis, adopting codes generated by the electronic case report forms. All patients gave their written informed consent to participate in the study.

Results

Baseline characteristics of the study population

Among the 10,669 subjects included in PITER cohort, 301 (2.8%) were migrants: 76 (25.2%) from Africa; 33 (11%) from Asia; 5 (1.7%) from America; 187 (62%) from Europe, 96.8% of whom ($n=181$) from East Europe. Romania ($n=79$, 26.2%), Egypt ($n=57$, 18.9%), Moldova ($n=49$, 16.3%) and Ukraine ($n=33$, 11%) were the main country of origin.

Demographic, virological and clinical characteristics of migrants compared to the native patients are shown in Table 1.

Table 1
Migrant and native patients baseline characteristics.

Characteristics		Migrants (N = 301*)		Natives (N = 10,368*)		p**	Adjusted*** O.R. (95% C.I.)
		Median	Range	Median	Range		
Age (years)		47	18–78	62	18–95	< 0.001	0.92 (0.91–0.93)
		N.	%	N.	%	p****	
Sex						< 0.001	
	Male (Ref.)	131	43.5	5670	54.7		
	Female	170	56.5	4698	45.3		2.49 (1.73–3.56)
BMI						< 0.05	
	Normal (Ref.)	125	41.5	5078	49.0		
	Underweight	8	2.7	188	1.8		1.03 (0.40–2.66)
	Overweight-Obese	168	55.8	5101	49.2		2.26 (1.58–3.24)
Genotype						< 0.001	
	≠ 4 (Ref.)	229	79.5	9081	94.0		
	4	59	20.5	578	6.0		2.51 (1.60–3.93)
HBsAg+						< 0.05	
	No (Ref.)	229	96.2	7967	98.6		
	Yes	9	3.8	113	1.4		2.67 (1.22–7.24)
HIV+						> 0.05	
	No (Ref.)	183	94.8	5110	90.8		
	Yes	10	5.2	517	9.2		0.29 (0.11–0.71)
Alcohol use						> 0.05	
	Never (Ref.)	203	68.4	6562	64.4		
	Current	48	16.2	1661	16.3		0.84 (0.53–1.33)
	Past	46	15.5	1969	19.3		0.70 (0.43–1.15)
Previous Interferon						< 0.05	
	No (Ref.)	242	80.4	7593	73.2		
	Yes	59	19.6	2775	26.8		0.82 (0.55–1.24)
Liver Stiffness value						< 0.001	
	≤ 14 KPa (Ref.)	220	73.1	6344	61.2		
	> 14 KPa§	81	26.9	4024	38.8		1.14 (0.77–1.71)

* For some variables inconsistencies are due to missing values.

** p value Mann–Whitney rank-sum test.

*** Adjusted for all variable listed in table.

**** p value Chi-square test.

§ Patients with liver cirrhosis diagnosed by clinical and/or instrumental findings for whom liver stiffness measurement was not available were included in the group >14 KPa.

Migrants were significantly younger (median age of 47 vs. 62, $p < 0.001$) and more frequently females (56.5% vs. 45.3%, $p < 0.001$) compared to Italians. Of 301 migrants, 168 (55.8%) were overweight or obese (defined as having a BMI of ≥ 25 Kg/m²) while natives were equally distributed between the normal (49%) and the overweight/obese group (49.2%).

No significant differences among migrants and native patients were observed for baseline alanine transaminase (ALT), aspartate transaminase (AST), platelet count, serum albumin, bilirubin, creatinine and international normalized ratio (INR) value (data not shown).

Genotype 1b was prevalent in both groups (53.5% and 48.9%, in migrants and natives respectively, $p > 0.05$). Genotype 1a and 2 were more frequently observed in native compared to migrant patients (12.1% vs. 6.6% and 19.1% vs. 5.2%, respectively) whereas genotype 4 was more frequent in migrants compared to natives (20.5%, vs. 6.0%, respectively) ($p < 0.001$).

No difference was found in the prevalence of anti-HBc positivity (anti-HBc⁺/HBsAg⁻) between migrants and natives (35.7% vs. 31.7%, respectively). A significantly higher HBsAg prevalence was detected in migrants (3.8%) compared to natives (1.4%) ($p < 0.05$).

After adjusting for potential confounding variables, HIV coinfection was significantly higher in native compared to migrant patients (OR: 0.29, 95% CI:0.11–0.71).

A higher prevalence of previous interferon-based treatment was reported for native compared to migrant patients (26.8% vs 19.6%, respectively; $p < 0.05$), nevertheless no difference was observed after adjusting for potential confounding variables.

Overall, 81 (26.9%) migrants and 4024 (38.8%) natives had liver cirrhosis diagnosis (liver stiffness value >14 KPa) ($p < 0.001$). However, this difference was not observed after adjusting for all variables considered by logistic regression analysis.

A similar C-P class distribution (C-P class A: 87% vs 82.2%; C-P class B/C: 13% vs. 17.8% in migrants and natives, respectively, $p > 0.05$) and a similar prevalence of decompensated cirrhosis (9.9% in migrants and 17.4% in natives, $p > 0.05$) were observed in both groups.

Similar rates of SVR12 were observed in migrants (98%) and natives (96%) patients ($p > 0.05$).

A comparison between migrants from East Europe vs others is shown in Supplementary Material. Migrant from East Europe were more frequently females and have different genotype pattern versus migrants from other geographical area, 50.5% of whom were infected by HCV genotype 4. Current alcohol use is more frequently reported in migrants from East Europe vs. others (Supplementary Table 1).

Comorbidity profile and cofactors for liver disease progression

Comorbidity profile in migrant and native patients is shown in Table 2. Autoimmune, cardiovascular, type 2 diabetes, dyslipidemias, endocrine, hematological, neurological and psychiatric disorders and tumors were more frequently reported in native compared with migrant patients ($p < 0.05$).

In patients who were treated with DAA, we found significant differences in comedication usage during and after antiviral treatment between natives and migrants: 60.9% of migrants and 45.9% of natives reported no comedication use ($p < 0.001$), whereas a higher percentage of natives compared to migrants assume more than 2 comedications (40.7% vs. 19.5%, $p < 0.001$).

The prevalence of potential factors for liver disease progression (i.e. HBsAg positivity, HIV coinfection, current alcohol abuse or surrogate markers of metabolic syndrome) after HCV eradication in the DAA treated migrants and native patients, is shown in Table 3. A significantly higher HBsAg positivity was detected in migrants compared to natives (3.1% vs. 1.2% in migrants and natives respectively, $p < 0.05$). Native patients reported a higher prevalence of potential metabolic syndrome compared to migrants (32.1% vs. 18.8% in natives and migrants respectively, $p < 0.05$). A total of 39.1% of migrants and 47.1% of native patients reported at least one of the above-mentioned factors for liver disease progression.

Table 2
Comorbidities distribution in migrant and native patients.

Comorbidities		Migrants (N = 301*)		Natives (N = 10,368*)		p*
		N.	%	N.	%	
Autoimmune	No	295	98.0	9909	95.6	< 0.05
	Yes	6	2.0	459	4.4	
Cardiovascular	No	256	85.0	6436	62.1	< 0.001
	Yes	45	15.0	3932	37.9	
Cerebrovascular	No	301	100.0	10,306	99.4	> 0.05
	Yes	0	0.0	62	0.6	
Dermatologic	No	301	100.0	10,319	99.5	> 0.05
	Yes	0	0.0	49	0.5	
Type 2 Diabetes	No	275	91.4	8896	85.8	< 0.05
	Yes	26	8.6	1472	14.2	
Dyslipidemia	No	293	97.3	9822	94.7	< 0.05
	Yes	8	2.7	546	5.3	
Endocrine	No	296	98.3	9866	95.2	< 0.05
	yes	5	1.7	502	4.8	
hematological	no	295	98.0	9840	94.9	< 0.05
	Yes	6	2.0	528	5.1	
Neurological	No	298	99.0	10,018	96.6	< 0.05
	Yes	3	1.0	350	3.4	
Psychiatric	No	294	97.7	9519	91.8	< 0.001
	Yes	7	2.3	849	8.2	
Renal	No	294	97.7	10,031	96.7	> 0.05
	Yes	7	2.3	337	3.3	
Respiratory	No	299	99.3	10,268	99.0	> 0.05
	Yes	2	0.7	100	1.0	
Tumors	No	294	97.7	9660	93.2	< 0.001
	Yes	7	2.3	708	6.8	
Others	No	259	86.0	8861	85.5	> 0.05
	Yes	42	14.0	1507	14.5	

* p value Chi-square test.

Table 3

Cofactors for liver disease progression in successfully DAA treated migrant and native patients.

	Migrants (N = 128)		Natives (N = 4896)		p*
	N.	%	N.	%	
HBsAg+	4	3.1	57	1.2	< 0.05
HIV+	6	4.7	290	5.9	> 0.05
Current alcohol use	19	14.8	740	15.1	> 0.05
Metabolic syndrome	24	18.8	1570	32.1	< 0.05
One or more cofactors	50	39.1	2304	47.1	> 0.05

* p value Chi-square test.

Discussion

In this study we evaluated data of migrants in care for chronic HCV infection, as reported by the PITER cohort. PITER has a prospective design, which consists of consecutively enrolled patients in care independently of antiviral treatment [14]. Migrants enrolled in this study are those linked to care and given the consecutive criteria in enrolment and the inclusion of clinical centers distributed all over Italy could be considered representative of migrants in care for HCV in Italy.

In the present study, migrants are younger and more frequently female compared to native patients with chronic hepatitis C infection. HCV Italian patients are also older compared to chronic infected patients diagnosed in other countries and this could be explained by different epidemiology, i.e. earlier epidemic wave of HCV infection through nosocomial infection in Italy compared to other countries, where the use of intravenous drugs is the main route of HCV transmission [17,18]. On the other side the younger age of migrants could also reflect the “healthy migrant effect” usually attributed to a self-selection process prior to migration [19].

In Italy, migrant domestic/care workers have increased drastically and according to data from the National Institute of Social

Security (INPS), 87.8% of them were women in 2015 [20]. This phenomenon could explain the higher percentage of female migrants observed in this cohort, especially in migrants from East Europe.

Regarding genotype distribution, although genotype 1, and in particular subtype 1b, is prevalent in both populations, genotype 4 is more prevalent in migrants, according to the observed high prevalence of migrants originating from Egypt (18.9%), where genotype 4 accounts for more than 90% of the HCV infections [3,4]. The genotype distribution has value in the epidemiological evaluation of chronic HCV infection in different populations, including routes of transmission as well as historic and current trends of human migrations. In our study, the SVR rate of patients was similar in migrant and native patients (98% and 96%, respectively), confirming that with the availability of pangenotypic DAAs, HCV genotype has no significant role as a predictor of treatment efficacy.

HCV may cause a variety of extrahepatic manifestations which need to be considered in the clinical assessment of HCV-infected Italian and migrant patients. The higher prevalence of comorbidities in natives could reflect the older age of natives vs. migrants, but underdiagnoses or difficulties in self-reporting of comorbidities in the migrant population cannot be excluded.

According to the EASL guidelines, other causes of chronic liver disease, or factors which are likely to affect the natural history or progression of liver disease and therapeutic choices, should be systematically investigated [12]. The presence of cofactors such as HBsAg positivity and HIV coinfection, previous and continuous alcohol abuse and the presence of metabolic syndrome are predictors of a potential liver disease progression and patients who have these cofactors should continue periodic clinical assessment independently of viral eradication. The HCV chronically infected migrants in care enrolled in PITER have a higher prevalence of HBsAg compared to natives, reflecting the HBV infection rate in the countries of origin [21]. Italy is a country with very low prevalence of HBV infection thanks to the improvement of the hygienic and socioeconomic con-

ditions and the introduction of compulsory vaccination and implemented surveillance policies [22–26], compared to other countries still lacking in effective vaccination campaigns. These data again underline testing for HBV infection with particular focus in the migrant population. All patients with chronic liver disease should be tested for HBV infection for three main reasons: a) surveillance of HBV reactivation during and after anti-HCV therapy, b) evaluation of the risk of liver disease progression despite HCV viral eradication and also c) prevention with HBV vaccination of other cohabitants and/or family members who are not immune.

Regarding HIV coinfection, native patients have a higher prevalence compared to migrant patients. Notably, we found that a total of 4741 (45.7%) of natives and 108 (35.8%) of migrants were not tested for HIV status. Native patients, for whom the HIV infection was not tested, were mainly patients older than 65 years and did not report risk factors for HIV infection. For migrant population whom are younger and with unknown risk factors, the lack of testing for HIV infection is of concern. Considering the blood born route of transmission and often the same risk factors for HCV and HIV, it is of crucial importance that HIV testing in patients with chronic HCV infection is undertaken. In the era of Highly Active Anti-Retroviral Therapy (HAART) and DAA therapies, continuous surveillance of HIV co-infection in newly and already diagnosed HCV-infected individuals, with particular focus in young aged natives and migrants, is compulsory considering the risk factors for HIV infection in recent years in Italy as well as in other European countries.

Notably, in successfully DAA treated patients about 40% of migrant and native patients reported one or more potential factors for liver disease progression. This specific finding should raise clinical awareness regarding the migrant population and their continuous follow-up after viral eradication to properly identify and address cofactors for liver disease progression, that are possibly underreported.

Study limitations

This study, based on the design of PITER cohort, focused on the already linked to care patients and those who already have had access to DAA therapy and could not give indications on the prevalence of HCV in migrant population or on different types of barriers that hinder the access of migrants to optimal health care services. The population under study is not representative of migrant population in Italy, but of migrants in care and for this reason we feel this study has an external validity only for migrant population already in care and not for the whole migrant population in Italy. In addition, a properly designed study should address the migrant populations including those legally or illegally living in Italy. Specific designed studies should focus the unlinked to care for HCV infection migrant patients, whose clinical and epidemiological profile may be different from those linked to care and herein described.

Conclusions

Although migrants have different demographics, HCV genotypes, viral coinfections and comorbidities, there are no treatment restrictions and differences in DAA efficacy rates vs. natives in Italy. It is important to properly address different comorbidities and maintain the clinical assessment in Italian and migrants with comorbidities and risk factors for liver disease progression after HCV eradication.

Funding

This study was funded by Italian Ministry of Health, Grant number RF-2016-02364053.

Declaration of Competing Interest

None

Acknowledgements

Authors wish to thank Giampaolo La Terza (Medisoftware Informatic Services) for Database maintenance and implementation.

This study was funded by Italian Ministry of Health, Grant number RF-2016-02364053.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dld.2021.03.020](https://doi.org/10.1016/j.dld.2021.03.020).

Appendix

PITER Collaborating group:

Cesare Mazzaro, Manuela Bertola, Ornella Schioppa (Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Pordenone)

Antonio Benedetti, Laura Schiada, Monica Cucco (Clinic of Gastroenterology and Hepatology, Marche Polytechnic University, Ancona)

Andrea Giacometti, Laura Brescini, Sefora Castelletti, Alessandro Fiorentini (Institute of Infectious Diseases and Public Health, Marche Polytechnic University, Ancona)

Gioacchino Angarano, Michele Milella (Clinic of Infectious Diseases, University Hospital, Bari)

Alfredo Di Leo, Maria Rendina, Fulvio Salvatore D'abramo, Chiara Lillo, Andrea Iannone, Mariano Piazzolla (Gastroenterology Unit, University Hospital of Bari, Bari)

Gabriella Verucchi, Lorenzo Badia (Clinic of Infectious Diseases and Microbiology Unit, Alma Mater Studiorum Bologna University, Bologna)

Fabio Piscaglia, Francesca Benevento, Ilaria Serio (Unit of Internal Medicine, Alma Mater Studiorum, University of Bologna, Bologna)

Francesco Castelli, Serena Zaltron, Angiola Spinetti, Silvia Odolini (Unit of Infectious and Tropical Diseases, University of Brescia, Brescia)

Raffaele Bruno, Mario Mondelli (Infectious and Tropical Disease Unit, Fondazione IRCCS Policlinico San Matteo, Pavia)

Luchino Chessa, Martina Loi (Liver Unit, University of Cagliari, Cagliari)

Carlo Torti, Chiara Costa, Maria Mazzitelli, Vincenzo Pisani, Vincenzo Scaglione, Enrico Maria Trecarichi (Unit of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro)

Anna Linda Zignego, Monica Monti, Francesco Madia (Department of Experimental and Clinical Medicine, Interdepartmental center MASVE, University of Florence, Florence)

Pier Luigi Blanc, Letizia Attala, Piera Pierotti, Elena Salomoni, Elisa Mariabelli (Infectious Disease Unit, S.M. Annunziata Hospital, Florence)

Teresa Antonia Santantonio, Serena Rita Bruno (Infectious Diseases Unit, Ospedali Riuniti, Foggia)

Ester Marina Cela (Department of Gastroenterology and Endoscopy, Ospedali Riuniti, Foggia)

Matteo Bassetti, Giovanni Mazzarello, Anna Ida Alessandrini, Antonio Di Biagio, Laura Ambra Nicolini (Infectious Diseases Division, San Martino Hospital, Genoa)

Giovanni Raimondo, Roberto Filomia (Department of Internal Medicine, University Hospital of Messina, Messina)

Alessio Aghemo, Rossella Meli (Internal Medicine and Hepatology Division, Humanitas Clinical and Research Center - IRCCS, Roz-

zano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Milan)

Adriano Lazzarin, Giulia Morsica, Stefania Salpietro (Department of Infectious Diseases, San Raffaele Hospital, Milan)

Massimo Galli (Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan)

Anna Ludovica Fracanzani, Erika Fatta, Rosa Lombardi (General Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan)

Pietro Lampertico, Marta Borghi, Roberta D'ambrosio, Elisabetta Degasperì (Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan)

Massimo Puoti, Chiara Baiguera, Federico D'amico (Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan)

Maria Vinci (Gastroenterology and Hepatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan)

Maria Grazia Rumi (Hepatology Unit, San Giuseppe Hospital, Milan)

Massimo Zuin, Alessia Giorgini, Paola Zermiani (Liver and Gastroenterology Unit, ASST Santi Paolo e Carlo, Milan)

Pietro Andreone, Paolo Caraceni, Marzia Margotti, Valeria Guarneri (Department of Internal Medicine, University Hospital of Modena, Modena)

Erica Villa, Veronica Bernabucci, Laura Bristot, Maria Luisa Paradiso (Department of Internal Medicine, Gastroenterology Unit, University of Modena and Reggio Emilia, Modena)

Guglielmo Migliorino, Ilaria Beretta, Alessandra Gambaro, Giuseppe Lapadula, Anna Spolti, Alessandro Soria (Infectious Diseases, San Gerardo Hospital - ASST Monza, Monza)

Pietro Invernizzi, Antonio Ciaccio, Martina LucÀ, Federica Malinverno, Laura Ratti (Gastroenterology and Hepatology, San Gerardo Hospital - ASST Monza, Monza)

Carmine Coppola, Daniela Caterina Amoruso, Federica Pisano, Ferdinando Scarano, Laura Staiano (Department of Hepatology, Gagnano Hospital, Naples)

Filomena Morisco, Valentina Cossiga (Gastroenterology Unit, University of Naples Federico II, Naples)

Ivan Gentile, Antonio Riccardo Buonomo, Maria Foggia, Emanuela Zappulo (Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples)

Alessandro Federico, Marcello Dallio (Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples)

Nicola Coppola, Caterina Sagnelli, Salvatore Martini, Caterina Monari (Infectious Diseases Division, University of Campania Luigi Vanvitelli, Naples)

Gerardo Nardone, Costantino Sgamato (Department of Gastroenterology, Federico II University of Naples, Naples)

Liliana Chemello, Luisa Cavalletto, Daniela Sterrantino (Department of Medicine, University of Padua, Padua)

Francesco Paolo Russo, Alberto Zanetto, Paola Zanaga (Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua)

Francesco Barbaro (Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padua)

Giuseppina Brancaccio (Department of Infectious Disease, University of Padua, Padua)

Antonio Craxì, Salvatore Petta, Vincenza Calvaruso, Luciano Crapanzano (Gastroenterology and Liver Unit, DiBiMIS, University of Palermo, Palermo)

Salvatore Madonia, Marco Cannizzaro, Erica Maria Bruno (Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo)

Anna Licata, Simona Amodeo, Adele Rosaria Capitano (Internal Medicine, AOUP Paolo Giaccone, Palermo)

Carlo Ferrari, Diletta Laccabue, Elisa Negri, Alessandra Orlandini, Marco Pesci (Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma)

Roberto Gulminetti, Layla Pagnucco (Institute of Infectious Diseases, University of Pavia, Pavia)

Giustino Parruti, Paola Di Stefano (Infectious Diseases Unit, Spirito Santo General Hospital, Pescara)

Maurizia Rossana Brunetto, Barbara Coco (Hepatology and Liver Physiopathology Laboratory and Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa)

Marco Massari, Romina Corsini, Elisa Garlassi (Infectious Diseases, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia)

Massimo Andreoni, Elisabetta Teti, Carlotta Cerva (Clinical Infectious Diseases, University of Tor Vergata, Rome)

Lorenzo Baiocchi, Xhimi Tata, Giuseppe Grassi (Department of Medical Sciences, University of Tor Vergata, Rome)

Antonio Gasbarrini, Maurizio Pompili, Martina De Siena (Internal Medicine, Gastroenterology and Hepatic Diseases Unit, Catholic University of Rome, Rome)

Gloria Taliani, Elisa Biliotti, Martina Spaziante (Infectious and Tropical Diseases Unit, Umberto I Hospital, "Sapienza" University, Rome)

Marcello Persico, Mario Masarone, Andrea Aglitti, Gemma Calvanese (Internal Medicine and Hepatology Unit, University of Salerno, Salerno)

Marco Anselmo, Pasqualina De Leo, Monica Marturano (Infectious Diseases Unit, San Paolo Hospital, Savona)

Giorgio Maria Saracco, Alessia Ciancio (Gastroenterology Unit, University of Turin, Turin)

Donatella Ieluzzi (Clinical Unit of Gastroenterology, University Hospital of Verona, Verona)

References

- [1] WHO global hepatitis report, 2017. <https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/2017>
- [2] Centers for Disease Control and Prevention. Surveillance for viral hepatitis - United States, 2014. 6 22, 2016. <https://www.cdc.gov/hepatitis/statistics/2014surveillance/commentary.htm#summary>
- [3] Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014;61:S45–57 j.
- [4] Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology* 2015;61:77–87.
- [5] Benvegñù L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 2004;53:744–9.
- [6] Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001;345:41–52.
- [7] European Centre for Disease Prevention and Control. Epidemiological Assessment of Hepatitis b and c Among Migrants in the EU/EEA. Stockholm: ECDC; 2016.
- [8] Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. *Eur J Intern Med* 2018;53:79–84.
- [9] Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med* 2014;370:211–21.
- [10] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014;370:1889–98.
- [11] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014;370:1483–93.
- [12] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. *J Hepatol* 2020;73:1170–218.
- [13] American Association for the Study of Liver Diseases, AASLD guidance: recommendations for Testing, Managing and Treating Hepatitis C. <http://www.hcvguidelines.org>.
- [14] Kondili LA, Vella SPITER Collaborating Group. PITER: an ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. *Dig Liver Dis* 2015;47:741–3.
- [15] Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005;41:48–54.

- [16] Dawson DA, Grant BF, Li TK. Quantifying the risks associated with exceeding recommended drinking limits. *Alcohol Clin Exp Res* 2005;29:902–8.
- [17] Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. *Hepatology* 1997;26:1006–11.
- [18] Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. *Gut* 1999;44:874–80.
- [19] Moullan Y, Jusot F. Why is the 'healthy immigrant effect' different between European countries? *Eur J Public Health* 2014;24(1):80–6 Suppl. PMID: 25108002. doi:10.1093/eurpub/cku112.
- [20] INPS data. Available in <https://www.dati.gov.it/dataset/lavoratori-domesticitipologia-rapporto-area-geografica-dati-trimestrali-2013-2014-4>.
- [21] Cuomo G, Franconi I, Riva N, et al. Migration and health: a retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy. *J Infect Public Health* 2019;12:200–4.
- [22] Zanetti AR, Tanzi E, Romano L, et al. Vaccination against hepatitis B: the Italian strategy. *Vaccine* 1993;11:521–4.
- [23] Bonanni P. Implementation in Italy of a universal vaccination programme against hepatitis B. *Vaccine* 1995;13(1):S68–71 Suppl.
- [24] Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. *Dig Liver Dis* 2005;37:622–7.
- [25] Zanetti AR, Romano L, Zappa A, et al. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. *J Clin Virol* 2006;36(1):S51–5 Suppl.
- [26] Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. *Vaccine* 2008;26:6266–73.